OverviewSuggest Edit

Cellular Biomedicine Group is a biopharmaceutical company that develops treatments for cancerous and degenerative diseases. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The Company develops treatments utilizing proprietary cell-based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell-specific dendritic cell therapy.
TypePublic
Founded2009
HQCupertino, CA, US
Websitecellbiomedgroup.com

Latest Updates

Employees (est.) (Dec 2018)193(+55%)
Revenue (FY, 2019)$339.9 K(+52%)
Share Price (Feb 2021)$19.8
Cybersecurity ratingAMore

Cellular Biomedicine Group Office Locations

Cellular Biomedicine Group has offices in Cupertino, Beijing, Shanghai and Hong Kong
Cupertino, CA, US (HQ)
19925 Stevens Creek Blvd #100
Beijing, CN
Nongda South Road
Shanghai, CN
333 Guiping Road
Hong Kong , HK
No. 8 Cotton Tree Drive
Show all (4)

Cellular Biomedicine Group Financials and Metrics

Cellular Biomedicine Group Revenue

Cellular Biomedicine Group's revenue was reported to be $339.92 k in FY, 2019
USD

Net income (Q2, 2020)

(13.5m)

EBIT (Q2, 2020)

(13.4m)

Market capitalization (25-Feb-2021)

384.7m

Closing stock price (25-Feb-2021)

19.8

Cash (30-Jun-2020)

13.6m

EV

390.6m
Cellular Biomedicine Group's current market capitalization is $384.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

35.5k9.4m564.4k2.5m627.9k336.8k224.4k339.9k

Cost of goods sold

213.2k1.9m860.4k162.2k135.8k62.4k

Gross profit

35.5k351.1k625.1k(232.5k)174.6k88.6k277.5k

Gross profit Margin, %

100%62%25%(37%)52%40%82%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

28.0k3.0k166.8k5.9m111.4k3.2m1.7m118.1k603.4k657.0k624.9k488.5k71.6k10.0k98.4k62.9k106.8k51.0k77.3k70.4k49.3k

Cost of goods sold

158.3k40.6k52.0k459.0k398.2k443.4k503.2k323.6k9.1k37.4k38.1k55.3k22.3k54.4k37.5k8.1k

Gross profit

28.0k3.0k3.0m1.7m66.1k144.4k258.7k181.5k(14.7k)(252.0k)884.061.0k24.8k51.5k28.7k22.9k32.9k41.2k

Gross profit Margin, %

100%100%95%98%56%24%39%29%(3%)(352%)9%62%39%48%56%30%47%84%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

602.7k757.5k7.2m14.8m14.9m39.3m21.6m52.8m15.4m

Accounts Receivable

2.6m10.6k141.0k630.3k412.7k202.9k787.0

Prepaid Expenses

50.0k56.9k565.3k367.1k1.9m1.7m835.0k

Inventories

119.1k372.2k390.9k
USDQ2, 2011

Financial Leverage

-7.2 x
Show all financial metrics

Cellular Biomedicine Group Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Cellular Biomedicine Group Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Cellular Biomedicine Group Online and Social Media Presence

Embed Graph

Cellular Biomedicine Group News and Updates

Rigrodsky & Long, P.A. Reminds Investors of Investigation of Cellular Biomedicine Group, Inc. Buyout

WILMINGTON, Del., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Cellular Biomedicine Group, Inc. (“CBMG”) (NASDAQ GS: CBMG) regarding possible breaches of fiduciary duties and other violations of law related to CBMG’s agreement to be acquired by a …

Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting

GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today...

Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members of CBMG management. If you are a CBMG investor, and would like...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cellular Biomedicine Group, Inc.

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc. ("CBMG" or the "Company") (NASDAQ: CBMG) in connection with the proposed interested-party...

Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

GAITHERSBURG, Md. and SHANGHAI, Aug. 12, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

Cellular Biomedicine Group (CBMG) Hosts R&D Showcase and Provides Updates to Clinical Programs

GAITHERSBURG, Md. and SHANGHAI, July 13, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, provided an...
Show more

Cellular Biomedicine Group Blogs

CBMG to Present on Three Panels at B. Riley FBR Annual Healthcare Conference

Cellular Biomedicine Group to Present on Three Panels at B. Riley FBR Annual Healthcare Conference  SHANGHAI, China and CUPERTINO, Calif., August 28, 2018 (GLOBE NEWSWIRE) — Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in t…

Second Quarter and First Half 2018 Financial Results and Business Highlights

Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights   China Food and Drug Administration (CFDA) Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T TherapyTargeting NHL and ALL Moved to New R&D Center i…

CBMG Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland

Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland SHANGHAI, China and CUPERTINO, Calif., June 22, 2018 (GLOBE NEWSWIRE) — Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical …

CBMG to Present a Keynote Address at CAR-TCR Summit Asia

CBMG to Present a Keynote Address at CAR-TCR Summit Asia SHANGHAI, China and CUPERTINO, Calif., June 21, 2018 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell thera…

Cellular Biomedicine Group Frequently Asked Questions

  • When was Cellular Biomedicine Group founded?

    Cellular Biomedicine Group was founded in 2009.

  • How many employees does Cellular Biomedicine Group have?

    Cellular Biomedicine Group has 193 employees.

  • What is Cellular Biomedicine Group revenue?

    Latest Cellular Biomedicine Group annual revenue is $339.9 k.

  • What is Cellular Biomedicine Group revenue per employee?

    Latest Cellular Biomedicine Group revenue per employee is $1.8 k.

  • Who are Cellular Biomedicine Group competitors?

    Competitors of Cellular Biomedicine Group include Taiho Pharmaceutical, Celltrion Healthcare and Astex Pharmaceuticals.

  • Where is Cellular Biomedicine Group headquarters?

    Cellular Biomedicine Group headquarters is located at 19925 Stevens Creek Blvd #100, Cupertino.

  • Where are Cellular Biomedicine Group offices?

    Cellular Biomedicine Group has offices in Cupertino, Beijing, Shanghai and Hong Kong.

  • How many offices does Cellular Biomedicine Group have?

    Cellular Biomedicine Group has 4 offices.